CD112 is a ligand of CD226 which is highly expressed in NK and T cells.[27] The binding of CD112–CD226 stimulates the NK cell‐mediated cytotoxicity.[28] As a chemokine, CXCL10 has been shown to activate NK cells and enhance their ability to kill dormant tumor cells.[29] Therefore, CAV1 inhibition‐enhanced anti‐MM activation of NK cells would result from the increase of SLAMF7, CD112, and CXCL10. Here, SLAMF7 is linked to Miyoshi myopathy.